Clinical trial
A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease
NCT03605667 is registered in ClinicalTrials.gov with Biohaven Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2018
- Completion date
- December 23, 2021
- Enrollment
- 350 (actual)
- Sites
- 44
Conditions
As the registry lists them; a condition with its own page is linked.